Our novel concept is the combination of a glyco-engineered anti-PD-L1 antibody with a second specificity directed against a tumor-specific antigen composed of a bispecific antibody construct, which would have the advantage that release of the PD-1/PD-L1 axis would be focused on the tumor site thereby potentially reducing side effects and increasing efficacy. This evidence concerns the gene CD274 and neoplasm.